{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:11:45Z","timestamp":1778227905123,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["GeroScience"],"DOI":"10.1007\/s11357-026-02300-0","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:30:02Z","timestamp":1778225402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists on the risk of incident dementia after acute kidney injury: a target-trial emulation"],"prefix":"10.1007","author":[{"given":"Ying-Ru","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng-Hong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jui-Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-0991","authenticated-orcid":false,"given":"Vin-Cent","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,8]]},"reference":[{"key":"2300_CR1","doi-asserted-by":"publisher","first-page":"1501175","DOI":"10.3389\/fmed.2024.1501175","volume":"11","author":"J Guo","year":"2024","unstructured":"Guo J, Liu Z, Wang P, Wu H, Fan K, Jin J, et al. Global, regional, and national burden inequality of chronic kidney disease, 1990\u20132021: a systematic analysis for the global burden of disease study 2021. Front Med (Lausanne). 2024;11:1501175.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"2300_CR2","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.2337\/dc17-2409","volume":"41","author":"YF Lin","year":"2018","unstructured":"Lin YF, Lin SL, Huang TM, Yang SY, Lai TS, Chen L, et al. New-Onset Diabetes After Acute Kidney Injury Requiring Dialysis. Diabetes Care. 2018Oct;41(10):2105\u201310.","journal-title":"Diabetes Care"},{"issue":"4","key":"2300_CR3","doi-asserted-by":"publisher","first-page":"406","DOI":"10.23876\/j.krcp.23.289","volume":"43","author":"SY Pan","year":"2024","unstructured":"Pan SY, Huang TT, Jiang ZH, Lin LC, Tsai IJ, Wu TL, et al. Unveiling the enigma of acute kidney disease: predicting prognosis, exploring interventions, and embracing a multidisciplinary approach. Kidney Res Clin Pract. 2024;43(4):406\u201316.","journal-title":"Kidney Res Clin Pract"},{"issue":"2","key":"2300_CR4","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1016\/S2468-2667(21)00249-8","volume":"7","author":"Collaborators GBDDF","year":"2022","unstructured":"Collaborators GBDDF. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health. 2022;7(2):e105\u201325.","journal-title":"Lancet Public Health"},{"issue":"1","key":"2300_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","volume":"12","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016Jan;12(1):60\u20134.","journal-title":"Alzheimers Dement"},{"issue":"10452","key":"2300_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(24)01296-0","volume":"404","author":"G Livingston","year":"2024","unstructured":"Livingston G, Huntley J, Liu KY, Costafreda SG, Selbaek G, Alladi S, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024Aug 10;404(10452):572\u2013628.","journal-title":"Lancet"},{"issue":"16","key":"2300_CR7","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2021.4001","volume":"325","author":"C BarbielliniAmidei","year":"2021","unstructured":"BarbielliniAmidei C, Fayosse A, Dumurgier J, Machado-Fragua MD, Tabak AG, van Sloten T, et al. Association Between Age at Diabetes Onset and Subsequent Risk of Dementia. JAMA. 2021Apr 27;325(16):1640\u20139.","journal-title":"JAMA"},{"issue":"2","key":"2300_CR8","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2023.2279647","volume":"45","author":"J Wang","year":"2023","unstructured":"Wang J, Xu X, Wang C, Ye D, Chen R, Peng P, et al. Association of acute kidney injury with the risk of cognitive impairment or dementia: a systematic review and meta-analysis. Ren Fail. 2023;45(2):2279647.","journal-title":"Ren Fail"},{"issue":"6","key":"2300_CR9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209751","volume":"103","author":"H Xu","year":"2024","unstructured":"Xu H, Eriksdotter M, Garcia-Ptacek S, Ferreira D, Ji D, Bruchfeld A, et al. Acute Kidney Injury and Its Association With Dementia and Specific Dementia Types: Findings From a Population-Based Study in Sweden. Neurology. 2024Sep 24;103(6):e209751.","journal-title":"Neurology"},{"issue":"7","key":"2300_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3673","volume":"39","author":"S Tian","year":"2023","unstructured":"Tian S, Jiang J, Wang J, Zhang Z, Miao Y, Ji X, et al. Comparison on cognitive outcomes of antidiabetic agents for type 2 diabetes: a systematic review and network meta-analysis. Diabetes Metab Res Rev. 2023;39(7):e3673.","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"2300_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70621","volume":"21","author":"N Nance","year":"2025","unstructured":"Nance N, Gilsanz P, Karter AJ, Finertie H, Schmittdiel JA, An J, et al. GLP-1RA comparative effectiveness against dementia onset relative to other antidiabetic medications in a large, multi-site cohort of patients with type 2 diabetes. Alzheimer\u2019s & Dementia. 2025;21(9):e70621.","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"5","key":"2300_CR12","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1001\/jamaneurol.2025.0353","volume":"82","author":"H Tang","year":"2025","unstructured":"Tang H, Donahoo WT, DeKosky ST, Lee YA, Kotecha P, Svensson M, et al. GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias. JAMA Neurol. 2025May 1;82(5):439\u201349.","journal-title":"JAMA Neurol"},{"issue":"7","key":"2300_CR13","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1016\/j.ekir.2022.04.094","volume":"7","author":"K Yau","year":"2022","unstructured":"Yau K, Dharia A, Alrowiyti I, Cherney DZI. Prescribing SGLT2 inhibitors in patients with CKD: expanding indications and practical considerations. Kidney Int Rep. 2022;7(7):1463\u201376.","journal-title":"Kidney Int Rep"},{"issue":"2","key":"2300_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024Jul 11;391(2):109\u201321.","journal-title":"N Engl J Med"},{"issue":"1","key":"2300_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.50050","volume":"7","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Huang TT, Sun CY, et al. Sodium-Glucose Cotransport Protein 2 Inhibitors in Patients With Type 2 Diabetes and Acute Kidney Disease. JAMA Netw Open. 2024Jan 2;7(1):e2350050.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2300_CR16","doi-asserted-by":"publisher","first-page":"5912","DOI":"10.1038\/s41467-024-50199-y","volume":"15","author":"HC Pan","year":"2024","unstructured":"Pan HC, Chen JY, Chen HY, Yeh FY, Sun CY, Huang TT, et al. GLP-1 receptor agonists\u2019 impact on cardio-renal outcomes and mortality in T2D with acute kidney disease. Nat Commun. 2024Jul 13;15(1):5912.","journal-title":"Nat Commun"},{"issue":"7624","key":"2300_CR17","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007Oct 20;335(7624):806\u20138.","journal-title":"BMJ"},{"issue":"24","key":"2300_CR18","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","volume":"328","author":"MA Hernan","year":"2022","unstructured":"Hernan MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA. 2022Dec 27;328(24):2446\u20137.","journal-title":"JAMA"},{"issue":"1","key":"2300_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1001\/jamainternmed.2024.6212","volume":"185","author":"Y Wang","year":"2025","unstructured":"Wang Y, Dalbeth N, Terkeltaub R, Zhang Y, Li X, Zeng C, et al. Target Serum Urate Achievement and Chronic Kidney Disease Progression in Patients With Gout and Kidney Disease. JAMA Intern Med. 2025Jan 1;185(1):74\u201382.","journal-title":"JAMA Intern Med"},{"issue":"26","key":"2300_CR20","doi-asserted-by":"publisher","first-page":"4824","DOI":"10.1002\/sim.7019","volume":"35","author":"X Mi","year":"2016","unstructured":"Mi X, Hammill BG, Curtis LH, Lai EC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016Nov 20;35(26):4824\u201336.","journal-title":"Stat Med"},{"issue":"5","key":"2300_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2025.108276","volume":"34","author":"PC Chiang","year":"2025","unstructured":"Chiang PC, Hsieh CY, Sung SF. Comparative risk of dementia in diabetic stroke patients prescribed SGLT2 vs. DPP-4 inhibitors: a propensity-matched retrospective cohort study. J Stroke Cerebrovasc Dis. 2025;34(5):108276.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"1","key":"2300_CR22","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s12933-023-02028-7","volume":"22","author":"E Xie","year":"2023","unstructured":"Xie E, Ye Z, Wu Y, Zhao X, Li Y, Shen N, et al. The triglyceride-glucose index predicts 1-year major adverse cardiovascular events in end-stage renal disease patients with coronary artery disease. Cardiovasc Diabetol. 2023Oct 27;22(1):292.","journal-title":"Cardiovasc Diabetol"},{"key":"2300_CR23","doi-asserted-by":"crossref","unstructured":"Morgan CJ. Landmark analysis: A primer. Journal of Nuclear Cardiology. 2019 2019\/04\/01;26(2):391\u201393.","DOI":"10.1007\/s12350-019-01624-z"},{"issue":"2","key":"2300_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/WAD.0000000000000103","volume":"30","author":"C Wang","year":"2016","unstructured":"Wang C, Gao S, Hendrie HC, Kesterson J, Campbell NL, Shekhar A, et al. Antidepressant use in the elderly is associated with an increased risk of dementia. Alzheimer Dis Assoc Disord. 2016;30(2):99\u2013104.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2300_CR25","doi-asserted-by":"publisher","unstructured":"Wang HG, Chen WH, Chang SH, Zhang T, Shao H, Guo J, Lo-Ciganic WH. Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study. BMC Geriatr. 2023;23(1):825. https:\/\/doi.org\/10.1186\/s12877-023-04475-z.","DOI":"10.1186\/s12877-023-04475-z"},{"issue":"10","key":"2300_CR26","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1111\/dom.16642","volume":"27","author":"A Sarwal","year":"2025","unstructured":"Sarwal A, Singh R, Wei G, Shen J, Nevers M, Hartsell SE, et al. Glycemic therapies and the risk of gastrointestinal adverse events in veterans with type 2 diabetes. Diabetes Obes Metab. 2025;27(10):5865\u201377.","journal-title":"Diabetes Obes Metab"},{"key":"2300_CR27","doi-asserted-by":"crossref","unstructured":"Andrade C. Mean Difference, Standardized Mean Difference (SMD), and Their Use in Meta-Analysis: As Simple as It Gets. J Clin Psychiatry. 2020 Sep 22;81(5).","DOI":"10.4088\/JCP.20f13681"},{"issue":"4","key":"2300_CR28","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med. 2017Aug 15;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"issue":"5","key":"2300_CR29","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1097\/EDE.0000000000000864","volume":"29","author":"MB Mathur","year":"2018","unstructured":"Mathur MB, Ding P, Riddell CA, VanderWeele TJ. Web site and R package for computing E-values. Epidemiology. 2018;29(5):e45\u20137.","journal-title":"Epidemiology"},{"issue":"3","key":"2300_CR30","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/13872877251319054","volume":"104","author":"EK Hui","year":"2025","unstructured":"Hui EK, Mukadam N, Kohl G, Livingston G. Effect of diabetes medications on the risk of developing dementia, mild cognitive impairment, or cognitive decline: a systematic review and meta-analysis. J Alzheimers Dis. 2025;104(3):627\u201348.","journal-title":"J Alzheimers Dis"},{"issue":"7","key":"2300_CR31","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1681\/ASN.2007080901","volume":"19","author":"M Liu","year":"2008","unstructured":"Liu M, Liang Y, Chigurupati S, Lathia JD, Pletnikov M, Sun Z, et al. Acute kidney injury leads to inflammation and functional changes in the brain. J Am Soc Nephrol. 2008;19(7):1360\u201370.","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"2300_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2025.101623","volume":"51","author":"M Sun","year":"2025","unstructured":"Sun M, Wang X, Lu Z, Yang Y, Lv S, Miao M, et al. Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer\u2019s disease, vascular dementia, and other dementia types among patients with type 2 diabetes. Diabetes Metab. 2025;51(2):101623.","journal-title":"Diabetes Metab"},{"key":"2300_CR33","doi-asserted-by":"crossref","unstructured":"Hirashima Y, Nakano T, Torisu K, Aihara S, Wakisaka M, Kitazono T. SGLT2 inhibition mitigates transition from acute kidney injury to chronic kidney disease by suppressing ferroptosis. Scientific Reports. 2024 2024\/09\/02;14(1):20386.","DOI":"10.1038\/s41598-024-71416-0"},{"key":"2300_CR34","doi-asserted-by":"crossref","unstructured":"Pawlos A, Broncel M, Wozniak E, Gorzelak-Pabis P. Neuroprotective Effect of SGLT2 Inhibitors. Molecules. 2021 Nov 28;26(23).","DOI":"10.3390\/molecules26237213"},{"key":"2300_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.823569","volume":"13","author":"JA Noel","year":"2022","unstructured":"Noel JA, Hougen I, Sood MM. The intersection of SGLT2 inhibitors, cognitive impairment, and CKD. Front Neurol. 2022;13:823569.","journal-title":"Front Neurol"},{"key":"2300_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102018","volume":"90","author":"F Mancinetti","year":"2023","unstructured":"Mancinetti F, Xenos D, De Fano M, Mazzieri A, Porcellati F, Boccardi V, et al. Diabetes-Alzheimer\u2019s connection in older age: SGLT2 inhibitors as promising modulators of disease pathways. Ageing Res Rev. 2023;90:102018.","journal-title":"Ageing Res Rev"},{"key":"2300_CR37","doi-asserted-by":"crossref","unstructured":"Zhang Y, Liao X, Xu J, Yin J, Li S, Li M, et al. The Promising Potency of Sodium-Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients. Biomedicines. 2024 Dec 6;12(12).","DOI":"10.3390\/biomedicines12122783"},{"issue":"4","key":"2300_CR38","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s00213-023-06341-7","volume":"240","author":"I Piatkowska-Chmiel","year":"2023","unstructured":"Piatkowska-Chmiel I, Herbet M, Gawronska-Grzywacz M, Pawlowski K, Ostrowska-Lesko M, Dudka J. Molecular and neural roles of sodium-glucose cotransporter 2 inhibitors in alleviating neurocognitive impairment in diabetic mice. Psychopharmacology. 2023;240(4):983\u20131000.","journal-title":"Psychopharmacology"},{"key":"2300_CR39","doi-asserted-by":"crossref","unstructured":"Mei J, Li Y, Niu L, Liang R, Tang M, Cai Q, et al. SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system. Translational Neurodegeneration. 2024 2024\/08\/09;13(1):41.","DOI":"10.1186\/s40035-024-00431-y"},{"key":"2300_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-079475","volume":"386","author":"A Shin","year":"2024","unstructured":"Shin A, Koo BK, Lee JY, Kang EH. Risk of dementia after initiation of sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in adults aged 40-69 years with type 2 diabetes: population based cohort study. BMJ. 2024;386:e079475.","journal-title":"BMJ"},{"issue":"1","key":"2300_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.2215\/CJN.11220720","volume":"16","author":"M Zhao","year":"2020","unstructured":"Zhao M, Sun S, Huang Z, Wang T, Tang H. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury. Clin J Am Soc Nephrol. 2020Dec 31;16(1):70\u20138.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2300_CR42","doi-asserted-by":"publisher","first-page":"386","DOI":"10.4093\/dmj.2025.0220","volume":"49","author":"JH Bae","year":"2025","unstructured":"Bae JH. SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: evolving evidence and clinical application. Diabetes Metab J. 2025;49(3):386\u2013402.","journal-title":"Diabetes Metab J"},{"issue":"8","key":"2300_CR43","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/j.ekir.2021.05.022","volume":"6","author":"H Liu","year":"2021","unstructured":"Liu H, Sridhar VS, Lovblom LE, Lytvyn Y, Burger D, Burns K, et al. Markers of kidney injury, inflammation, and fibrosis associated with Ertugliflozin in patients with CKD and diabetes. Kidney Int Rep. 2021;6(8):2095\u2013104.","journal-title":"Kidney Int Rep"},{"issue":"1","key":"2300_CR44","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12933-020-01197-z","volume":"20","author":"T Yamada","year":"2021","unstructured":"Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, et al. Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovasc Diabetol. 2021Jan 7;20(1):14.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2300_CR45","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M18-3136","volume":"171","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Kim D, Fralick M, Tong A, Patorno E. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Ann Intern Med. 2019Aug 20;171(4):248\u201356.","journal-title":"Ann Intern Med"},{"issue":"9","key":"2300_CR46","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1002\/ejhf.2584","volume":"24","author":"D Vukadinovic","year":"2022","unstructured":"Vukadinovic D, Abdin A, Anker SD, Rosano GMC, Mahfoud F, Packer M, et al. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2022;24(9):1625\u201332.","journal-title":"Eur J Heart Fail"},{"key":"2300_CR47","doi-asserted-by":"crossref","unstructured":"Natale P, Tunnicliffe DJ, Toyama T, Palmer SC, Saglimbene VM, Ruospo M, et al. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2024 May 21;5(5):CD015588.","DOI":"10.1002\/14651858.CD015588.pub2"},{"key":"2300_CR48","doi-asserted-by":"crossref","unstructured":"Natale P, Green SC, Tunnicliffe DJ, Pellegrino G, Toyama T, Strippoli GF. Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes. Cochrane Database Syst Rev. 2025 Feb 18;2(2):CD015849.","DOI":"10.1002\/14651858.CD015849.pub2"},{"issue":"4","key":"2300_CR49","doi-asserted-by":"publisher","first-page":"525","DOI":"10.4093\/dmj.2025.0242","volume":"49","author":"JA Kim","year":"2025","unstructured":"Kim JA, Yoo HJ. Exploring the side effects of GLP-1 receptor agonist: to ensure its optimal positioning. Diabetes Metab J. 2025;49(4):525\u201341.","journal-title":"Diabetes Metab J"}],"container-title":["GeroScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11357-026-02300-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11357-026-02300-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:30:18Z","timestamp":1778225418000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11357-026-02300-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,8]]},"references-count":49,"alternative-id":["2300"],"URL":"https:\/\/doi.org\/10.1007\/s11357-026-02300-0","relation":{},"ISSN":["2509-2723"],"issn-type":[{"value":"2509-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,8]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}